
Opinion|Videos|February 5, 2025
Recent FDA Approvals in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how FDA approvals have expanded options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), with pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec-vncg offering new immunotherapy and gene therapy approaches.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How has the treatment landscape of NMIBC changed in recent years to provide better options for patients?
- Provide an overview of recent FDA approvals, including for the treatment of high-risk, BCG-unresponsive NMIBC (pembrolizumab [PD-1 inhibitor], nogapendekin alfa inbakicept-pmln [immunotherapy], and nadofaragene firadenovec-vncg [gene therapy]).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
2
Registry launches to assess real-world clinical utility of ArteraAI Prostate Test
3
Published LITESPARK-011 data show PFS benefit with belzutifan plus lenvatinib in ccRCC
4
Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC
5









